Dahal K, et al. - Using standard techniques, a systematic review and meta-analysis were performed to determine the role of therapy with aldosterone antagonists in patients with ST-segment elevation myocardial infarction (STEMI) without heart failure. They searched PubMed, Embase, CINAHL, and Cochrane Central databases and a manual search was performed for relevant references from the selected articles and published reviews was performed from database inception through June 2017. For this analysis, randomized clinical trials that evaluated treatment with aldosterone antagonists in patients with STEMI without clinical heart failure or left ventricular ejection fraction (LVEF) greater than 40% were involved. It was observed in the findings that treatment with aldosterone antagonists was associated with a mortality benefit in patients with STEMI with LVEF greater than 40% or without heart failure.